Skip to content

Clinical trials

Hyperparathyroidism, Secondary trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hyperparathyroidism, Secondary Clear all

183 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20011
20024
20032
20045
20055
200610
200710
200811
200913
201015
201113
20129
20139
20149
201510
20163
20178
20185
20195
20203
20214
20224
20239
20248
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed137
Unknown status16
Terminated15
Recruiting8
Withdrawn4
Not yet recruiting2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Amgen33
Abbott13
AbbVie (prior sponsor, Abbott)12
Kyowa Kirin Co., Ltd.7
OPKO Health, Inc.7
KAI Pharmaceuticals5
OPKO IP Holdings II, Inc.5
Shanghai Hengrui Pharmaceutical Co., Ltd.5
Genzyme, a Sanofi Company4
Shaanxi Micot Pharmaceutical Technology Co., Ltd.4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hyperparathyroidism, Secondary183
Renal Insufficiency, Chronic72
Kidney Failure, Chronic36
Hyperparathyroidism23
Chronic Kidney Disease-Mineral and Bone Disorder15
Vitamin D Deficiency13
Renal Insufficiency12
Kidney Diseases11
Hypocalcemia9
Parathyroid Diseases8

Trials

Showing 26 to 50 of 183. Each trial links to its page on Pharma Observatory.

83 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.